{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Mild"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Moderate"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Severe"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"The cumulative incidence of chronic GvHD will be estimated using Kalbfleisch-Prentice method. Death is the competing risk event. The severity of chronic GvHD will be described. Chronic GvHD was evaluated using NIH Consensus Global Severity Scoring.\" The number of participants with incidence by severity is given.","groups":[{"description":"Participants undergo a conditioning regimen with cyclophosphamide, fludarabine, aldesleukin (interleukin-2), natural killer cell therapy, anti-thymocyte globulin, rituximab, thiotepa, and melphalan prior to transplantation of T-cell depleted HPC transplant on day 0 and CD45RA-depleted HPC transplant on day 1. Beginning Day 6 post-transplant, patients receive G-CSF daily until ANC recovers to normal level.\n\nCyclophosphamide: Given intravenously (IV)\n\nFludarabine: Given IV\n\nG-CSF: Given IV or subcutaneously (SQ)\n\nInterleukin-2: Given SQ\n\nMelphalan: Given IV\n\nThiotepa: Given IV\n\nRituximab: Given IV\n\nNatural killer cell therapy: Given IV\n\nT-cell depleted HPC transplant: T-cell depleted hematopoietic stem cells will be infused on day 0.\n\nCD45RA-depleted HPC transplant: CD45RA depleted stem cells will be infused on day 1.","id":"OG000","title":"Participants"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"one year post transplantation","title":"Incidence and Severity of Chronic GvHD","type":"SECONDARY","unitOfMeasure":"participants"}